Key Points
- CEO Kevin McNamara sold 2,000 Chemed shares at an average price of $501.40, generating $1.0 million; he retained 68,418 shares after the transaction.
- Chemed reported stronger-than-expected quarterly results, with adjusted EPS of $6.06 and revenue of $673.25 million, up 8.8% year over year. The company raised its quarterly dividend from $0.60 to $0.70 per share.
- Wall Street maintains a consensus “Hold” rating, with an average price target of $530.75; institutional investors own approximately 95.85% of the company.
Chemed Corporation (NYSE:CHE - Get Free Report) CEO Kevin Mcnamara sold 2,000 shares of the company's stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $501.40, for a total value of $1,002,800.00. Following the sale, the chief executive officer owned 68,418 shares in the company, valued at approximately $34,304,785.20. This trade represents a 2.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Chemed Price Performance
CHE stock opened at $499.50 on Tuesday. The business's 50-day moving average is $523.14 and its two-hundred day moving average is $456.37. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.91 and a quick ratio of 0.89. The firm has a market capitalization of $6.53 billion, a P/E ratio of 25.09, a P/E/G ratio of 2.03 and a beta of 0.51. Chemed Corporation has a 1 year low of $365.20 and a 1 year high of $557.00.
Chemed (NYSE:CHE - Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The company reported $6.06 EPS for the quarter, topping analysts' consensus estimates of $5.60 by $0.46. Chemed had a return on equity of 31.77% and a net margin of 10.60%.The business had revenue of $673.25 million during the quarter, compared to the consensus estimate of $665.04 million. During the same period in the previous year, the company posted $4.27 earnings per share. The business's revenue for the quarter was up 8.8% on a year-over-year basis. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. Analysts anticipate that Chemed Corporation will post 23.55 earnings per share for the current fiscal year.
Chemed Increases Dividend
The company also recently declared a quarterly dividend, which was paid on Thursday, September 3rd. Shareholders of record on Monday, August 17th were issued a dividend of $0.70 per share. This is a boost from Chemed's previous quarterly dividend of $0.60. The ex-dividend date was Monday, August 17th. This represents a $2.80 annualized dividend and a yield of 0.6%. Chemed's dividend payout ratio (DPR) is presently 14.06%.
Wall Street Analysts Forecast Growth
A number of brokerages have recently weighed in on CHE. Wall Street Zen lowered shares of Chemed from a "strong-buy" rating to a "buy" rating in a report on Saturday. Bank of America reiterated a "neutral" rating on shares of Chemed in a research note on Wednesday, July 29th. Oppenheimer increased their target price on Chemed from $500.00 to $590.00 and gave the company an "outperform" rating in a report on Friday, July 31st. Royal Bank Of Canada raised their target price on Chemed from $436.00 to $548.00 and gave the stock a "sector perform" rating in a research report on Thursday, July 30th. Finally, Weiss Ratings upgraded shares of Chemed from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, July 17th. One analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, Chemed currently has a consensus rating of "Hold" and an average target price of $530.75.
View Our Latest Report on Chemed
Institutional Investors Weigh In On Chemed
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Monetary Solutions Ltd acquired a new stake in shares of Chemed in the fourth quarter valued at approximately $25,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Chemed in the 2nd quarter valued at $34,000. Versant Capital Management Inc raised its position in Chemed by 7,500.0% in the 2nd quarter. Versant Capital Management Inc now owns 76 shares of the company's stock valued at $35,000 after purchasing an additional 75 shares during the last quarter. Keating Financial Advisory Services Inc. purchased a new stake in Chemed in the 2nd quarter valued at $36,000. Finally, MassMutual Private Wealth & Trust FSB raised its position in Chemed by 65.3% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 81 shares of the company's stock valued at $38,000 after purchasing an additional 32 shares during the last quarter. Hedge funds and other institutional investors own 95.85% of the company's stock.
About Chemed
(
Get Free Report)
Chemed Corporation is a diversified holding company that operates businesses in the healthcare and residential and commercial services industries. Its primary operations are conducted through VITAS Healthcare and Roto-Rooter.
VITAS Healthcare provides hospice and palliative care for patients with advanced illnesses. Its services are delivered in patients' homes, hospice residences, nursing facilities, hospitals and other care settings, primarily throughout the United States. Care is provided by interdisciplinary teams that may include physicians, nurses, hospice aides, social workers and chaplains.
Roto-Rooter provides plumbing and drain-cleaning services, as well as water cleanup and related services for residential and commercial customers.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
